The J.P. Morgan Healthcare Conference got off to a rousing start with the announcement of several deals on the first day, but the overall tone of the meeting was subdued as investors continued to worry about how some of the biggest names in pharma will navigate looming patent cliffs, a lack of bigger M&A, the financing environment for smaller biotechs, and an uncertain US policy outlook under a new administration.
Deals And Sunshine At J.P. Morgan, But Biopharma Outlook Remains Mixed
Initial excitement over a few small deals announced at the opening of J.P. Morgan tapered off as approaching exclusivity losses, a lack of big takeouts and political uncertainty weighed on sentiment.
More from J.P. Morgan
• By
Bristol Myers Squibb has been in a rapid growth phase to make up for upcoming losses of exclusivity. Scrip spoke with executives about further catalysts coming in the next 18-24 months.
• By
Lilly’s revenue is rising rapidly based on its successes in diabetes and obesity, and the company is reinvesting in big plays in those markets as well as in cancer, lipid-lowering and other indications.
• By
Despite a big market opportunity with an underserved patient population, investment in the therapeutic area lags and investor perception is a pressure point.
• By
Repatha was not an overnight success, but the work Amgen has done to turn its PCSK9 inhibitor into a blockbuster is informing its strategy for Lp(a)-reducing olpasiran and obesity drug MariTide.